Snibe launches Maglumi SARS-CoV-2 neutralizing antibody

Snibe announced that the Maglumi SARS-CoV-2 neutralizing antibody assay is available in CE accepting areas. The fully automatic Maglumi SARS-CoV-2 neutralizing antibody assay aims to detect neutralizing antibodies against the SARS-CoV-2, which indicate the immune status of the vaccine receivers and the COVID-19 patients. Different from the traditional neutralizing antibody detection method-the plaque-reduction neutralization test (PRNT), which requires BSL-3 laboratories and may take up to 5 days to complete, Maglumi SARS-CoV-2 neutralizing antibody are capable of providing the first result within 20 mins when combined with Maglumi CLIA analyzers.

Neutralizing antibodies reduce viral infectivity by binding to the surface epitopes of viral particles and blocking the entry of the virus to an infected cell, so it is critical to measure the presence of neutralizing antibodies quantitatively to assess the protective immune response after natural infection or vaccine injection. Now the COVID-19 vaccine is moving closer to large-scale rollout worldwide, the company is proud to add the Maglumi SARS-CoV-2 neutralizing antibody assay in the comprehensive Maglumi SARS-CoV-2 diagnostic portfolio, and help guide clinical decision making in the combat of the COVID-19.